Patents by Inventor Elie Dheilly

Elie Dheilly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240400720
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: January 8, 2024
    Publication date: December 5, 2024
    Inventors: Krzysztof M. MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • Publication number: 20240150489
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 9, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI
  • Publication number: 20240141062
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 2, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI, Cyrille DREYFUS
  • Patent number: 11840553
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 12, 2023
    Assignee: Novimmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Publication number: 20220089767
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Laure Bouchez, Blandine Pouleau, Marie-Agnes Doucey, Elie Dheilly, Stanislas Blein, Cian Stutz, Carole Estoppey, Jeremy Loyau, Thierry Monney, Camille Grandclement, Stefano Sammicheli
  • Patent number: 11059910
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 13, 2021
    Assignee: NovImmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Publication number: 20180355065
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 13, 2018
    Applicant: NovImmune S.A.
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • Publication number: 20180291116
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • Publication number: 20180291115
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • Publication number: 20140303354
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: December 3, 2013
    Publication date: October 9, 2014
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois